Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with ixazomib for high-risk multiple myeloma has completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-01-21